Clinical Webinar Series: Medication abortion between 14 0/7 and 27 6/7 weeks of gestation

Overview

Dr. Blake Zwerling and Dr. Malavika Prabhu present on the Society of Family Planning Clinical Recommendation: Medication abortion between 14 0/7 and 27 6/7 weeks of gestation, jointly developed with the Society for Maternal-Fetal Medicine. The webinar is moderated by Dr. Audrey Merriam.

Objectives

By the end of the webinar, viewers will be able to:

- Define the best practices for medication abortion between 14 0/7 and 27 6/7 weeks gestation.

- Discuss the expected patient outcomes for different regimens of medication abortion.

- Apply recommended considerations when counseling patients between 14 0/7 and 27 6/7 weeks gestation seeking medication abortion.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Society of Family Planning and Society for Maternal-Fetal Medicine. The Society of Family Planning is accredited by the ACCME to provide continuing medical education for physicians.

Society of Family Planning designates this internet enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Webinar information

Released: January 1, 2024

Expires: December 31, 2026

Acknowledgement of commercial support

No commercial support was received in the production of this activity.

Disclosure Summary

Blake Zwerling, MD, MS – Presenter and Reviewer: No relevant financial relationships

Malavika Prabhu, MD – Presenter and Reviewer: Receives royalties with UptoDate; Consulting Fees with BabyList, Inc.

Alison Edleman, MD, MPH – Author and Reviewer: No relevant financial relationships

Anwar Jackson, MD, MS – Author and Reviewer: No relevant financial relationships

Anne Burke, MD, MPH – Author and Reviewer: Research with Merck, Exeltis/Chemo; Consulting Fees with Exeltis.

Audrey Merriam, MD, MS – Moderator and Reviewer: No relevant financial relationships

Akila Subramaniam, MD - Reviewer: Research with Billion To One; Consulting Fees with Novocuff, Inc.

Celeste Durnwald, MD - Reviewer: Research with United Health Group and Helmsley Charitable Trust; Receives royalties with Up To Date; Consulting Fees with Dexcom GDM Advisory Board